Haier Biomedical Secures First Korean Pharmaceutical Order

On June 24, 2025, Haier Biomedical won the bid for a project with the Stem Cell Research Institute, a leading-edge biotechnology company in South Korea. The company completed a one-time delivery of 88 units of equipment, ranging from cryogenic storage systems to laboratory apparatus. This not only marks Haier Biomedical's debut in the Korean pharmaceutical market but also its step forward in expanding its presence in the international market through its innovative service model.

Top-tier pharma's equipment procurement dilemma: How can manufacturers escape the "card collection game"?

The Stem Cell Research Institute is a major player in the biomedical field, with operations spanning cell culture, storage, biopharmaceutical R&D, and the production of human cell-based cosmetics, beverages, and foods. With facilities and institutions in the United States, Japan, and South Korea — including cell banks and treatment hospitals — the institute has achieved notable breakthroughs in treating immune-related diseases such as heart conditions and Parkinson's, and holds nine international patents.

However, meeting its vast and complex production demands means building a comprehensive, closed loop R&D-to-manufacturing ecosystem. But here lies the challenge: traditional procurement models — where companies source equipment in batches from multiple suppliers — bring inefficiencies and complicate management, slowing down production. The process is often likened to a "card collection game," where companies are forced to piece together equipment from various suppliers, spending enormous time and effort, only to struggle with performance shortfalls.

Haier Biomedical delivers breakthrough: One-stop, full-chain solution

With integrated solutions in high demand, Haier Biomedical has taken the lead by offering a complete product portfolio and extensive experience in delivering fully integrated solutions. For the Stem Cell Research Institute, the company provided a fully customized suite of laboratory equipment, fulfilling all procurement requirements in a single order.

The benefits of this one-stop solution are immediate:

It greatly shortens construction timelines and accelerates production, enabling faster time-to-market and helping businesses gain a competitive edge. A single brand and service contact also minimizes the coordination costs often associated with managing multiple suppliers, eliminating concerns over miscommunication or unclear responsibilities. Most importantly, Haier Biomedical's proven technology and service infrastructure ensure the efficient operation of the facility, allowing enterprises to concentrate fully on R&D and production.

Milestone breakthrough: A new chapter in the global biopharmaceutical industry

Haier Biomedical's first successful bid for a Korean pharmaceutical plant marks a major milestone — not only as a breakthrough in Korea's high-end pharmaceutical manufacturing market, but also as a testament to the company's internationalization strategy and integrated solution capabilities.

Looking ahead, Haier Biomedical's model that emphasizes core values and the integration of professional expertise is poised to become a key driver in advancing the global biopharmaceutical industry. Well-positioned to promote greater efficiency and synergy across the industry, the company is expected to bring new changes and opportunities on a global scale — set to play an even more prominent role on the international stage.